| $350M | ||
| $217M | ||
| $172M | ||
| $109M | ||
| $107M | ||
| $104M |
Buys | $22,935 | 3 | 7 |
Sells | $4,845,407 | 39 | 93 |
| FREEMAN KEVIN D | director | 1 | $19,514 | 0 | $0 | $19,514 |
| ELDRED KARY | director | 2 | $3,421 | 0 | $0 | $3,421 |
| CALLICUTT JACK W | Chief Financial Officer | 0 | $0 | 9 | $474,087 | $-474,087 |
| LEWIS JOEL | President and CEO | 0 | $0 | 10 | $620,536 | $-620,536 |
| Jamil Khurram | Chief Medical Officer | 0 | $0 | 11 | $1M | $-1M |
| 10X Fund, L.P. | 10 percent owner | 0 | $0 | 4 | $1.34M | $-1.34M |
| Shlevin Harold H. | director | 0 | $0 | 7 | $1.44M | $-1.44M |
Galectin Therapeutics Inc. is a biopharmaceutical company in the clinical development phase, dedicated to discovering and advancing new therapies for a spectrum of illnesses, including fibrotic disorders and various cancers. The company's flagship therapeutic agent is belapectin (GR-MD-02), an inhibitor of galectin-3, which is a complex polysaccharide polymer. This compound is currently undergoing Phase III clinical trials, assessing its effectiveness in treating liver scarring linked to fatty liver disease and non-alcoholic steatohepatitis …
Over the last 12 months, insiders at Galectin Therapeutics Inc. have bought $22,935 and sold $4.85M worth of Galectin Therapeutics Inc. stock.
On average, over the past 5 years, insiders at Galectin Therapeutics Inc. have bought $51,411 and sold $1.32M worth of stock each year.
Highest buying activity among insiders over the last 12 months: FREEMAN KEVIN D (director) — $19,514. ELDRED KARY (director) — $3,421.
The last purchase of 300 shares for transaction amount of $810 was made by ELDRED KARY (director) on 2026‑02‑06.
| 2026-07-14 | Sale | Jamil Khurram | Chief Medical Officer | 16,250 0.0237% | $5.13 | $83,285 | -31.09% | |
| 2026-06-29 | Sale | Shlevin Harold H. | director | 22,268 0.0343% | $5.04 | $112,231 | -24.95% | |
| 2026-06-29 | Sale | Jamil Khurram | Chief Medical Officer | 47,467 0.0731% | $5.04 | $239,234 | -24.95% | |
| 2026-06-26 | Sale | Shlevin Harold H. | director | 7,732 0.0118% | $5.00 | $38,660 | -24.95% | |
| 2026-06-26 | Sale | Jamil Khurram | Chief Medical Officer | 2,533 0.0039% | $5.00 | $12,665 | -24.95% | |
| 2026-06-23 | Sale | Jamil Khurram | Chief Medical Officer | 7,557 0.0115% | $3.14 | $23,729 | +20.51% | |
| 2026-05-26 | Sale | Jamil Khurram | Chief Medical Officer | 568 0.001% | $3.10 | $1,761 | +31.00% | |
| 2026-02-06 | ELDRED KARY | director | 300 0.0004% | $2.70 | $810 | +12.14% | ||
| 2026-01-06 | Sale | LEWIS JOEL | President and CEO | 37,698 0.054% | $3.58 | $134,853 | -9.13% | |
| 2026-01-06 | Sale | CALLICUTT JACK W | Chief Financial Officer | 20,354 0.0299% | $3.67 | $74,695 | -9.13% | |
| 2026-01-06 | Sale | Jamil Khurram | Chief Medical Officer | 21,446 0.0313% | $3.65 | $78,205 | -9.13% | |
| 2026-01-05 | Sale | LEWIS JOEL | President and CEO | 27,731 0.0434% | $3.91 | $108,342 | -19.07% | |
| 2026-01-05 | Sale | CALLICUTT JACK W | Chief Financial Officer | 25,732 0.0401% | $3.90 | $100,298 | -19.07% | |
| 2026-01-05 | Sale | Jamil Khurram | Chief Medical Officer | 25,499 0.0398% | $3.90 | $99,408 | -19.07% | |
| 2026-01-02 | Sale | LEWIS JOEL | President and CEO | 18,571 0.0291% | $4.20 | $77,939 | -22.47% | |
| 2026-01-02 | Sale | CALLICUTT JACK W | Chief Financial Officer | 13,914 0.0218% | $4.20 | $58,394 | -22.47% | |
| 2026-01-02 | Sale | Jamil Khurram | Chief Medical Officer | 13,055 0.0205% | $4.20 | $54,789 | -22.47% | |
| 2025-12-31 | Sale | Jamil Khurram | Chief Medical Officer | 8,125 0.0126% | $4.07 | $33,089 | -24.52% | |
| 2025-12-23 | ELDRED KARY | director | 700 0.001% | $3.73 | $2,611 | -21.05% | ||
| 2025-12-23 | FREEMAN KEVIN D | director | 5,500 0.0075% | $3.55 | $19,514 | -21.05% |
| LEWIS JOEL | President and CEO | 832592 1.2642% | $2.79M | 7 | 12 | <0.0001% |
| ELDRED KARY | director | 65682 0.0997% | $220,034.70 | 13 | 0 | +25.64% |
| FREEMAN KEVIN D | director | 55269 0.0839% | $185,151.15 | 31 | 0 | +4.03% |
| CALLICUTT JACK W | Chief Financial Officer | 7614 0.0116% | $25,506.90 | 4 | 18 | <0.0001% |
| Shlevin Harold H. | director | 6500 0.0099% | $21,775.00 | 2 | 17 | +120% |
| Martin Rod D | director | 9357422 14.2087% | $31.35M | 1 | 4 | <0.0001% |
| Uihlein Richard E | 7893191 11.9854% | $26.44M | 6 | 0 | <0.0001% | |
| CZIRR JAMES C | 10 percent owner | 5922207 8.9925% | $19.84M | 3 | 30 | <0.0001% |
| FIRTEL BURTON C | director | 129000 0.1959% | $432,150.00 | 3 | 0 | +32.75% |
| ROME JERALD K | director | 117344 0.1782% | $393,102.40 | 2 | 0 | +11.02% |
| Greenberg Arthur | director | 109445 0.1662% | $366,640.75 | 6 | 0 | <0.0001% |
| TRABER PETER G | President & CEO | 107333 0.163% | $359,565.55 | 11 | 2 | +22.8% |
| OMENN GILBERT S | director | 66769 0.1014% | $223,676.15 | 1 | 2 | <0.0001% |
| SMITH DAVID H | director | 63500 0.0964% | $212,725.00 | 1 | 0 | <0.0001% |
| AMELIO GILBERT F | director | 60614 0.092% | $203,056.90 | 1 | 6 | +7.71% |
| Zordani Richard A. Jr. | director | 42083 0.0639% | $140,978.05 | 7 | 0 | +8.59% |
| CHRISTIAN MILDRED S | director | 27500 0.0418% | $92,125.00 | 1 | 0 | <0.0001% |
| CONAWAY DALE H | director | 22806 0.0346% | $76,400.10 | 4 | 0 | <0.0001% |
| MAULDIN JOHN F | director | 18074 0.0274% | $60,547.90 | 12 | 0 | +77.12% |
| Rubin Marc | director | 13581 0.0206% | $45,496.35 | 3 | 4 | +24.3% |
| MCGAULEY THOMAS | Chief Financial Officer | 10000 0.0152% | $33,500.00 | 1 | 0 | <0.0001% |
| PRESSLER HERMAN PAUL | director | 9500 0.0144% | $31,825.00 | 1 | 0 | <0.0001% |
| PLATT DAVID | Chairman & CEO | 6000 0.0091% | $20,100.00 | 3 | 1 | +15% |
| FOLEY MAUREEN | Chief Operating Officer | 5000 0.0076% | $16,750.00 | 1 | 0 | +26.27% |
| Gourzis James Theophile | director | 2000 0.003% | $6,700.00 | 1 | 0 | 0% |
| ZUCCONI THEODORE DANIEL | director | 1083 0.0016% | $3,628.05 | 3 | 1 | +8.35% |
| Schwartz Elissa J. | 1000 0.0015% | $3,350.00 | 1 | 0 | <0.0001% |
Galectin Therapeutics Inc. (GALT) | $22,710,871 | 107 | 8.53% | $220.62M |
$6,146,922 | 96 | -4.70% | $233.68M | |
$19,239,249 | 50 | -2.24% | $238.33M | |
$168,352,523 | 35 | 13.58% | $218.79M | |
$54,828,550 | 26 | -13.88% | $201.12M |
| Increased Positions | 52 | +53.06% | 2M | +20.62% |
| Decreased Positions | 37 | -37.76% | 1M | -11.39% |
| New Positions | 24 | New | 1M | New |
| Sold Out Positions | 15 | Sold Out | 566,757 | Sold Out |
| Total Postitions | 113 | +15.31% | 12M | +9.23% |
| Vanguard Group Inc | $9,104.00 | 3.51% | 2.25M | +63,419 | +2.9% | 2025-09-30 |
| Osaic Holdings, Inc. | $4,960.00 | 1.91% | 1.22M | -40,660 | -3.21% | 2025-09-30 |
| Blackrock, Inc. | $3,231.00 | 1.25% | 797,669 | -94,210 | -10.56% | 2025-09-30 |
| Geode Capital Management, Llc | $2,564.00 | 0.99% | 633,067 | -33,124 | -4.97% | 2025-09-30 |
| Marshall Wace, Llp | $2,245.00 | 0.87% | 554,261 | +523,861 | +1,723.23% | 2025-09-30 |
| Wealthspire Advisors, Llc | $1,942.00 | 0.75% | 479,518 | 0 | 0% | 2025-09-30 |
| Susquehanna International Group, Llp | $1,809.00 | 0.7% | 446,578 | +253,378 | +131.15% | 2025-09-30 |
| Lpl Financial Llc | $1,459.00 | 0.56% | 360,268 | -6,710 | -1.83% | 2025-09-30 |
| Geneos Wealth Management Inc. | $1,459.00 | 0.56% | 360,175 | -63,060 | -14.9% | 2025-09-30 |
| Commonwealth Equity Services, Llc | $1,194.00 | 0.46% | 294,901 | +9,487 | +3.32% | 2025-09-30 |